Related references
Note: Only part of the references are listed.Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors
Pascal Wolter et al.
ACTA ONCOLOGICA (2009)
Time course of imaging changes of GBM during extended bevacizumab treatment
Suchitra Ananthnarayan et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
John M. L. Ebos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors
Joachim Drevs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Michael R. Mancuso et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
W Fiedler et al.
BLOOD (2005)
Share Paper
